136 related articles for article (PubMed ID: 36280425)
21. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
22. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer.
Mie T; Ozaka M; Okamoto T; Takeda T; Ushida Y; Mori C; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Sasaki T; Inoue Y; Takahashi YU; Sasahira N
In Vivo; 2022; 36(6):2844-2851. PubMed ID: 36309391
[TBL] [Abstract][Full Text] [Related]
23. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
[TBL] [Abstract][Full Text] [Related]
25. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery.
Inoue Y; Saiura A; Oba A; Ono Y; Mise Y; Ito H; Sasaki T; Ozaka M; Sasahira N; Takahashi Y
J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):143-155. PubMed ID: 33058515
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer.
Saito K; Isayama H; Sakamoto Y; Nakai Y; Ishigaki K; Tanaka M; Watadani T; Arita J; Takahara N; Mizuno S; Kogure H; Ijichi H; Tateishi K; Tada M; Hasegawa K; Fukayama M; Kokudo N; Koike K
Med Oncol; 2018 May; 35(7):100. PubMed ID: 29846849
[TBL] [Abstract][Full Text] [Related]
28. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
[TBL] [Abstract][Full Text] [Related]
30. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Okada K; Takahashi S; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):801-811. PubMed ID: 28314992
[TBL] [Abstract][Full Text] [Related]
33. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
34. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
Dong LP; Liu YM; Lu WJ; Tang KZ
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(17):6316-6327. PubMed ID: 36111933
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
Tas F; Karabulut S; Ciftci R; Sen F; Sakar B; Disci R; Duranyildiz D
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1163-71. PubMed ID: 24647734
[TBL] [Abstract][Full Text] [Related]
37. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
Okada KI; Shimokawa T; Hirono S; Kawai M; Sho M; Satoi S; Matsumoto I; Eguchi H; Murakami Y; Yamada S; Doi M; Yamaue H;
Oncology; 2017; 93(5):343-346. PubMed ID: 28719890
[TBL] [Abstract][Full Text] [Related]
38. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(4):604-611. PubMed ID: 33479765
[TBL] [Abstract][Full Text] [Related]
39. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer.
AlMasri S; Zenati M; Hammad A; Nassour I; Liu H; Hogg ME; Zeh HJ; Boone B; Bahary N; Singhi AD; Lee KK; Paniccia A; Zureikat AH
JAMA Netw Open; 2022 Jun; 5(6):e2218355. PubMed ID: 35737385
[TBL] [Abstract][Full Text] [Related]
40. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Walpole I; Lee B; Shapiro J; Thomson B; Lipton L; Ananda S; Usatoff V; Mclachlan SA; Knowles B; Fox A; Wong R; Cooray P; Burge M; Clarke K; Pattison S; Nikfarjam M; Tebbutt N; Harris M; Nagrial A; Zielinski R; Chee CE; Gibbs P
Asia Pac J Clin Oncol; 2023 Feb; 19(1):214-225. PubMed ID: 35831999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]